Last $5.07 USD
Change Today -0.08 / -1.55%
Volume 110.8K
RTIX On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 8:10 PM 09/17/14 All times are local (Market data is delayed by at least 15 minutes).

rti surgical inc (RTIX) Snapshot

Open
$5.13
Previous Close
$5.15
Day High
$5.20
Day Low
$5.00
52 Week High
09/2/14 - $5.58
52 Week Low
10/31/13 - $2.77
Market Cap
288.1M
Average Volume 10 Days
116.8K
EPS TTM
$-0.41
Shares Outstanding
56.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for RTI SURGICAL INC (RTIX)

rti surgical inc (RTIX) Related Bloomberg News

View More Bloomberg News

rti surgical inc (RTIX) Related Businessweek News

No Related Businessweek News Found

rti surgical inc (RTIX) Details

RTI Surgical, Inc., together with its subsidiaries, produces and sells orthopedic and other surgical implants that repair and promote the natural healing of human bone and other human tissues. It processes donated human musculoskeletal and other tissues, including bone, cartilage, tendon, ligament, fascia lata, pericardium, sclera, and dermal tissues, as well as bovine and porcine animal tissues to produce allograft and xenograft implants by utilizing its proprietary BIOCLEANSE, TUTOPLAST, and CANCELLE SP sterilization processes. The company’s implants are used in the fields of spine, sports medicine, surgical specialties, bone graft substitutes and general orthopedic, dental, and ortho fixation. RTI Surgical, Inc. markets its products through its direct distribution force, as well as through a network of independent distributors to hospitals and surgeons in the United States and internationally. The company was formerly known as RTI Biologics, Inc. and changed its name to RTI Surgical, Inc. in July 2013. RTI Surgical, Inc. was founded in 1997 and is headquartered in Alachua, Florida.

1,100 Employees
Last Reported Date: 03/10/14
Founded in 1997

rti surgical inc (RTIX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $547.0K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $332.3K
Executive Vice President of North American Sa...
Total Annual Compensation: $327.7K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $330.1K
Executive Vice President of Administration an...
Total Annual Compensation: $328.4K
Compensation as of Fiscal Year 2013.

rti surgical inc (RTIX) Key Developments

RTI Surgical Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Earnings Guidance for the Third Quarter of 2014; Revised Earnings Guidance for the Year 2014

RTI Surgical Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported revenues of $66 million compared to $42.3 million for the second quarter of 2013. Operating income was $4.410 million against operating loss of $4.295 million a year ago. Income before income tax benefit was $3.925 million against loss before income tax expense of $4.292 million a year ago. Net income applicable to common shares was $1.577 million or $0.03 per diluted share against net loss applicable to common shares of $2.999 million or $0.05 per diluted share a year ago. Net cash provided by operating activities was $2.622 million against $3.279 million a year ago. Purchases of property, plant and equipment was $3.536 million against $2.164 million a year ago. Patent and acquired intangible asset costs was $0.059 million against $0.136 million a year ago. For the six months, the company reported revenues of $126.774 million against $82.731 million a year ago. Operating income was $0.922 million against operating loss of $3.233 million a year ago. Income before income tax benefit was $0.082 million against loss before income tax expense of $3.230 million a year ago. Net loss applicable to common shares was $1.483 million or $0.03 per diluted share against net loss applicable to common shares of $1.537 million or $0.03 per diluted share a year ago. Net cash used in operating activities was $0.685 million against $4.784 million against Purchases of property, plant and equipment was $8.472 million against $4.872 million a year ago. Patent and acquired intangible asset costs was $0.276 million against $0.234 million a year ago. The company revised full year revenue guidance for 2014. The company now expects full year revenues for 2014 to be between $258 million and $261 million, as compared to prior guidance of between $248 million and $253 million. Full year net income per fully diluted common share is expected to be in the range of $0.03 to $0.05, based on 57 million fully diluted shares outstanding. Excluding an inventory purchase price accounting adjustment taken in the first quarter of 2014, full year net income per fully diluted common share is expected to be in the range of $0.09 to $0.11. For 2014, the company anticipates being cash flow positive from operations. On a non-GAAP basis, full year net income per fully diluted common share is expected to be in the range of $0.09 to $0.11, based on $57 million fully diluted common shares outstanding, an increase for prior guidance of $0.07 to $0.09. For the third quarter of 2014, the company expects revenues to be between $64 million and $65 million and net income per fully diluted common share to be approximately $0.02. The company expects net income per fully diluted common share for the third quarter of 2014 to be approximately $0.02.

RTI Surgical Inc. Unveils AlloWedge(TM) Bicortical Bone Wedges and Instrumentation Set at APMA Annual Meeting

RTI Surgical Inc. is unveiling the new AlloWedge(TM) bicortical bone wedges and instrumentation set at the American Podiatric Medical Association (APMA) annual scientific meeting in Honolulu this week. AlloWedge grafts offer surgeons an alternative option for opening wedge osteotomies in the foot and ankle. The AlloWedge bicortical grafts are pre-shaped and designed specifically for Cotton and Evans osteotomy procedures. The instrument set includes a full line of high quality instruments aimed at simplifying the procedure and decreasing overall preparation time. The AlloWedge instrument set includes a wide footprint distractor, featuring a textured surface for a more controlled grip, and osteotomes with a sharp serrated edge, allowing for clean cuts. Also included are trials that match the size and shape of the graft to reduce errors in graft selection, tamps that include a textured surface to reduce slippage when inserting the grafts into place and a mallet that is balanced for control and accuracy.

RTI Surgical Inc. to Report Q2, 2014 Results on Jul 24, 2014

RTI Surgical Inc. announced that they will report Q2, 2014 results at 9:00 AM, Eastern Standard Time on Jul 24, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RTIX:US $5.07 USD -0.08

RTIX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alphatec Holdings Inc $1.87 USD +0.04
Bacterin International Holdings Inc $4.99 USD -0.31
ICU Medical Inc $62.36 USD +0.08
Merit Medical Systems Inc $12.54 USD +0.16
Orthofix International NV $32.13 USD +1.02
View Industry Companies
 

Industry Analysis

RTIX

Industry Average

Valuation RTIX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.2x
Price/Book 1.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RTI SURGICAL INC, please visit www.rtisurgical.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.